Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics
https://www.sciencedirect.com/science/article/pii/S0889159126007816
A summary of the above paper:
Psychedelics Silence Systemic Inflammation Only When the Body Is Under Fire
A systematic review and meta-analysis published in Brain, Behavior, and Immunity evaluated 61 studies examining how serotonergic psychedelics alter immune function across laboratory dishes, animal models, and clinical trials. The quantitative synthesis revealed that classical psychedelics act as context-dependent immunomodulators rather than universal anti-inflammatory agents. In animal models with active inflammation, psychedelics induced a massive reduction in primary pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha. Conversely, healthy animals and baseline-healthy humans showed no meaningful anti-inflammatory benefit, with high doses occasionally provoking transient immune activation. The findings indicate that psychedelic therapy does not suppress normal immune surveillance, but translation to human clinical longevity remains unproven due to underpowered trials and publication bias.
For years, the longevity and biohacking communities have speculated that classical psychedelics do far more than rewire neural synapses. Anecdotal accounts and isolated bench assays suggested that compounds like psilocybin, LSD, and dimethyltryptamine possessed powerful systemic anti-inflammatory properties, potentially serving as interventions against age-related chronic inflammation, or inflammaging. A rigorous meta-analysis led by researchers at the University of California, San Francisco and the Mental Health Centre Copenhagen delivers a grounded, data-driven reality check.
The overarching insight of this investigation is that serotonergic psychedelics are not blanket anti-inflammatory drugs in the mold of corticosteroids or biological inhibitors. Instead, they act as state-dependent immunomodulators. Across 18 animal studies analyzed, psychedelic compounds caused an aggressive reduction in systemic and central nervous system inflammation, but this effect occurred strictly when the organism was subjected to an active inflammatory challenge, such as bacterial endotoxin, tissue ischemia, or allergic asthma. When administered to healthy, unstressed animals, the exact same compounds produced no reduction in inflammatory cytokines. At elevated dosages or under chronic exposure regimens, some compounds even triggered mild pro-inflammatory shifts.
This distinction is fundamental for health optimization. The primary mechanism of action operates through the serotonin 2A receptor and the sigma-1 receptor, which are present on peripheral immune cells, including monocytes, macrophages, and dendritic cells. Under normal homeostasis, basal signaling through these receptors does not suppress cytokine expression. However, when tissue injury or pathogenic insults upregulate serotonin 2A receptor density, psychedelic receptor agonism actively interrupts inflammatory cascades, downregulating downstream cytokine production.
The human clinical evidence, however, reveals a stark translational bottleneck. Across ten clinical trials encompassing 278 human subjects, evidence of consistent anti-inflammatory efficacy was largely absent. Out of ten trials, four observed no significant changes in inflammatory markers, three reported anti-inflammatory trends, and three recorded transient pro-inflammatory spikes, characterized by acute elevations in natural killer cells and circulating white blood cells within the first several hours of dosing.
The primary explanation for this discordance is that human clinical trials have almost exclusively enrolled healthy volunteers or psychiatric cohorts with normal baseline inflammatory profiles. In the single trial where participants presented with verified, elevated baseline C-reactive protein, ayahuasca administration produced a clear reduction in systemic inflammation.
Furthermore, the preclinical animal literature displays distinct signs of small-study publication bias, meaning the magnitude of the animal benefit is likely overstated. Psychedelic molecules undeniably demonstrate remarkable efficacy in extinguishing acute inflammatory fires in animal tissue. However, anyone claiming that routine microdosing or macrodosing acts as a preventative anti-inflammatory regimen in healthy humans is running far ahead of validated clinical science.
Actionable Insights
For individuals pursuing healthspan extension, this study provides three practical takeaways regarding systemic inflammation and psychedelic pharmacology.
First, psychedelics should not be used as preventative anti-inflammatory supplements by healthy individuals. In healthy rodent models, psychedelics produced zero measurable reduction in inflammatory cytokines, yielding an effect size of negative 0.06 standard deviations, which is statistically indistinguishable from zero. Routine exposure in the absence of an inflammatory trigger will not lower baseline inflammatory markers.
Second, the therapeutic window for psychedelic immunomodulation is restricted to states of verified immune elevation. In animal models with induced pathology, psychedelic exposure suppressed inflammatory cytokines by 1.23 standard deviations compared to controls. This corresponds to an approximate 40 to 60 percent absolute reduction in circulating levels of interleukin-6 and tumor necrosis factor-alpha. In humans, meaningful biomarker reductions were observed only in subjects presenting with baseline high-sensitivity C-reactive protein levels exceeding 3.0 milligrams per liter.
Third, high dosages and chronic exposure carry tangible inflammatory risks. Animal studies utilizing dosages exceeding 5.0 milligrams per kilogram or daily dosing over several weeks induced pro-inflammatory marker elevation and oxidative stress. Biohackers should verify baseline inflammatory status via high-sensitivity C-reactive protein and cytokine panels before assuming any immunomodulatory utility.
Context and Source
Open Access Paper: Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics."
The lead research institutions include the Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences at the University of California San Francisco (United States), the San Francisco Veterans Affairs Medical Center (United States), and the Copenhagen Research Center for Biological and Precision Psychiatry at Copenhagen University Hospital (Denmark).
The impact score of this journal is 7.5, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.